diaDexus Announces Presentations on Novel Cancer Markers at the 96th Annual Meeting of the American Association for Cancer Research
Posted on: Friday, 15 April 2005, 18:00 CDT
SOUTH SAN FRANCISCO, Calif., April 15 /PRNewswire/ -- diaDexus announced today multiple presentations highlighting novel cancer markers and discovery methodologies. The presentations will take place at the 96th Annual Meeting of the American Association for Cancer Research (AACR) being held April 16-20, 2005 at the Anaheim Convention Center in Anaheim, CA.
The presentations are as follows:
Sunday, April 17, 2005
Poster Session: Molecular Markers in Diagnosis and Prognosis 1:
Gastrointestinal Malignancies (Colorectal, Gastric, Pancreatic, and
Hepatocellular)
Title: Evaluation of DcR3 (DD-C248) as a serum diagnostic biomarker for
colon cancer
Abstract #1259: 1:00 p.m. - 5:00 p.m.
Monday, April 18, 2005
Poster Session: Cancer Profiling and Therapeutics
Title: A novel splice variant of human Ep-CAM as a potential therapeutic
antibody target for epithelial cell-based cancers
Abstract #2706: 1:00 p.m. - 5:00 p.m.
Tuesday, April 19, 2005
Poster Session: Molecular Genetics 4: Reproductive Cancers
Title: B7-H4 (DD-0110) is overexpressed in uterine endometrioid
carcinomas independent of tumor grade, T cell infiltration, or apoptotic
index
Abstract #3604: 8:00 a.m. - 12:00 p.m.
Poster Session: Molecular Markers in Diagnosis and Prognosis 6:
Gynecologic and Epithelial Cancers
Title: Evaluation of B7-H4 (DD-O110) as a prognostic marker in tissue
and serum of ovarian cancer patients
Abstract #4882: 1:00 p.m. - 5:00 p.m.
About diaDexus
diaDexus, a privately held biotechnology company, based in South San Francisco, California, is focused on the discovery, development and commercialization of novel, patent-protected diagnostic and therapeutic products with high clinical value. The PLAC(TM) test, developed by diaDexus, is a blood test cleared by the U.S. Food and Drug Administration to aid in the prediction of an individual's risk for a coronary event, in conjunction with clinical evaluation and patient risk assessment. The PLAC test is currently available through laboratories nationwide. For more information about the PLAC test visit http://www.plactest.com/. More information about the company may be found at http://www.diadexus.com/.
diaDexus, Inc.
CONTACT: Patrick Plewman of diaDexus, Inc., +1-650-246-6415; or CarolynBumgardner Wang of WeissComm Partners, cell, +1-415-225-5050, or office,+1-415-692-4218, or carolyn@weisscommpartners.com, for diaDexus, Inc.
Web site: http://www.diadexus.com/
Source: PRNewswire
Related Articles
- Data From Three Clinical Studies of bioTheranostics' Breast Cancer Molecular Test Presented at CTRC-AACR San Antonio Breast Cancer Symposium
- Cancer Screening Tests Could Do More Harm Than Good: Reader's Digest April Cover Story
- ScreenCancer Adds InSure(R) FIT(TM) Colorectal Cancer Screening Test to European Cancer Screening Program
- Previstage(TM) GCC Colorectal Cancer Staging Test Featured in Expert Reviews Article
- Ciphergen Initiates Clinical Trial for Ovarian Cancer Triage Test
- Agendia Receives U.S. FDA Clearance for MammaPrint Breast Cancer Diagnostic Test
- Biomoda, Inc., Maker of Early Lung Cancer Detection Test, Begins Trading on OTC-BB Under Symbol 'BMOD'
- More Than Half of Survey Respondents Said They Are Concerned With the Accuracy of Prostate Cancer Screening Tests
- Agendia's MammaPrint(R) Shows Significant Agreement With Other Multi-Gene Breast Cancer Prognosis Tests
- Nextel Cup Spies Invading Privacy: Secrets Hard to Keep With Open-Test Sessions
 |
 |
User Comments (0)
RSS Feeds